LOTTE Biologics Presents ADC Platform,

SoluFlex Link™, Research Results at AACR

Seoul, South Korea, April 15, 2026 — LOTTE Biologics announced that it will present research findings on its antibody-drug conjugate (ADC) platform technology, SoluFlex Link™, at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from April 17 to 22 in San Diego, USA.

Alongside ASCO (American Society of Clinical Oncology) and ESMO (European Society for Medical Oncology), AACR is recognized as one of the world’s leading oncology conferences, bringing together global experts and industry leaders to discuss advances in cancer research and therapeutics.

At the conference, LOTTE Biologics will present results evaluating the structural stability of ADCs developed in collaboration with Kanaph Therapeutics, incorporating the SoluFlex Link™ technology.

According to the company, analysis of aggregation behavior over time showed that control groups without the SoluFlex Link™ exhibited increasing aggregation, whereas ADCs incorporating the technology demonstrated significantly reduced aggregation and maintained high stability. These findings indicate that SoluFlex Link™ can assist in ensuring consistent product quality during storage and distribution.

In addition, cell-based studies targeting multiple markers, including epidermal growth factor receptor (EGFR) and trophoblast cell-surface antigen 2 (TROP-2), showed that ADCs utilizing SoluFlex Link™ achieved superior anti-tumor efficacy at lower concentrations compared to those without the technology. Notably, enhanced efficacy was also observed in triple-negative breast cancer (TNBC) cell models.

Furthermore, pharmacokinetic (PK) studies in animal models demonstrated improved in vivo activity supported by enhanced stability. These results suggest that ADCs developed using SoluFlex Link™ may offer improved anti-cancer efficacy and pharmacological properties.

“SoluFlex Link™ represents a differentiated platform that may overcome the limitations of conventional linker technologies,” said a LOTTE Biologics representative. “By enhancing hydrophilicity and improving stability and performance, we believe it validates its potential as a versatile ADC platform, enabling our partners and clients to successfully develop next-generation ADCs.”

LOTTE Biologics continues to conduct joint research on SoluFlex Link™ with Kanaph Therapeutics.